Prostate adenocarcinoma · line 1 · Olaparib monotherapy (mCRPC, HRR-mutant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-OLAPARIB-MONO`

ID	`IND-PROSTATE-MCRPC-1L-PARPI`
Type	Indication
Status	status not declared
Diseases	`DIS-PROSTATE`
Sources	`SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Notes

PROfound: olaparib post-ARPI in HRR-mutant mCRPC. BRCA1/2 (Cohort A) largest benefit; broader HRR (Cohort B) smaller benefit. Talazoparib + enzalutamide (TALAPRO-2) and niraparib + abiraterone (MAGNITUDE) alternative HRR-mutant regimens. Reimbursement gap in Ukraine for prostate-specific PARPi indication.

Used By

Algorithms

ALGO-PROSTATE-MCRPC-1L - ALGO-PROSTATE-MCRPC-1L

Handbook Chapters

HB-PROSTATE-MCRPC-1L - Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning

Handbook Questions

HQ-PROSTATE-MCRPC-1L-002 - HQ-PROSTATE-MCRPC-1L-002

Indication

IND-PROSTATE-MCRPC-2L-PARPI - IND-PROSTATE-MCRPC-2L-PARPI